Literature DB >> 327043

Abnormalities of the local immune system in intestinal neoplasia: a morphological study.

F H Green, S Whitehead, H Fox.   

Abstract

In colonic adenocarcinomata abnormalities have been noted in all morphological aspects of the local immune system of the bowel; thus, in such tumours there is a defective production of secretory IgA, a diminished content of secretory component (SC) and a marked decrease in intraepithelial lymphocytes. By contrast, no such abnormalities were noted in the non-neoplastic areas of the bowel, either immediately adjacent to, or some distance from, the carcinoma. These findings suggest that there is not usually any generalised morphological abnormality of the local immune systems in intestinal neoplasia and that the immunological abnormalities noted within the tumour are a result of the changed nature of the epithelium, thus altering, or interfering with, the normal interactions between epithelial and lymphoid tissue in the gut.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 327043     DOI: 10.1002/path.1711220202

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  3 in total

1.  Immunohistochemical evaluation of carcinoembryonic antigen, secretory component, and epithelial IgA in ulcerative colitis with dysplasia.

Authors:  T O Rognum; K Elgjo; O Fausa; P Brandtzaeg
Journal:  Gut       Date:  1982-02       Impact factor: 23.059

2.  Plasma carcinoembryonic antigen concentrations and immunohistochemical patterns of epithelial marker antigens in patients with large bowel carcinoma.

Authors:  T Rognum; K Elgjo; P Brandtzaeg; H Orjasaeter; A Bergan
Journal:  J Clin Pathol       Date:  1982-09       Impact factor: 3.411

3.  Large-bowel carcinomas with different ploidy, related to secretory component, IgA, and CEA in epithelium and plasma.

Authors:  T O Rognum; E Thorud; K Elgjo; P Brandtzaeg; H Orjasaeter; K Nygaard
Journal:  Br J Cancer       Date:  1982-06       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.